Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan in Combination With Immune Checkpoint Inhibition for Maintenance Treatment of Participants With Mismatch Repair Proficient (MMRp) Endometrial Cancer

NCT07684599 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07684599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07684599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan in Combination With Immune Checkpoint Inhibition for Maintenance Treatment of Participants With Mismatch Repair Proficient (MMRp) Endometrial Cancer
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 3, 2026
Completion date
September 18, 2031
Enrollment
610 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, endometrial